Technology

Utilizing peptide technology platform to engineer drug-like characteristics (or qualities)

Our peptide technology platform is built multiple tools, methods, and proprietary know-how that enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, manufacturability, and also engineer oral stability as desired with specific peptidomimetic and chemical modifications. These tools and techniques include:

  • Molecular design tools and large virtual libraries of conformationally constrained scaffolds, collectively known as Vectrix™—originally developed in the Australian laboratory of Mark Smythe, our co-founder, it allows for the de novo selection of peptide scaffolds as starting points against specific targets based on computational matching to functional structural components of the intended targets
  • Random/structure-based libraries and phage display techniques—allows for the discovery and optimization of peptide hits and leads in a de novo and/or focused manner
  • Oral stability assaysin vitro and ex vivo assays and in vivo systems that allow us to explore peptide liabilities by simulating chemical and biological degradative mechanisms, and physical barriers that constrained peptides must overcome for oral stability and absorption
  • Formulation—integration of known and novel technologies to deliver stable peptides through oral, subcutaneous, and rectal dosage forms to optimize treatment options for patients
  • Medicinal, computational, and structural peptide chemistry—allows optimization and refinement of potency, selectivity, oral and plasma stability and GI restriction
  • In vivo and ex vivo pharmacology studies, including GI restriction—involving tools to quantify compound concentrations and activity in various GI tissue compartments and feces to develop oral products with GI stability and maximal local and minimal systemic exposure

To date, our proprietary platform has generated several product candidates that exemplify reproducibility and broad scope:

  • PTG-300—injectable hepcidin peptide mimetic for rare blood disorders
  • PN-943—oral alfa-4-beta-7-integrin antagonist for IBD
  • PTG-200 (JNJ-67864238), PN-232 (JNJ-75105186) and PN-235 (JNJ-77242113)—IL-23 receptor antagonists for IBD with strategic options for development in multiple indications

We will continue to use our platform to discover novel peptides against targets where small molecules or injectable biologics do not present viable opportunities for drug discovery or offer satisfactory outcomes to patients.